76 results on '"Hrapkowicz, T."'
Search Results
2. Elderly patients with severe aortic stenosis - does moderate mitral regurgitation require simultaneous surgical intervention?
- Author
-
Kwiecien, A, primary, Kubacki, K A, additional, Krason, M Z, additional, Kaczmarczyk, M, additional, Glanowski, M, additional, Hirnle, G, additional, Rychter, J, additional, Pakula, R J, additional, Aidibi, A, additional, Jakimowicz, K M, additional, Barnak, A, additional, and Hrapkowicz, T B, additional
- Published
- 2023
- Full Text
- View/download PDF
3. (952) Hospital-To-Hospital Sharing of Patients with Cardiogenic Shock Bridged with Ecmella
- Author
-
Kosiorowska, K., primary, Bochenek, M., additional, Bielicki, G., additional, Zakliczyński, M., additional, Hrapkowicz, T., additional, Kuliczkowski, W., additional, and Przybylski, R., additional
- Published
- 2023
- Full Text
- View/download PDF
4. (503) Donor-Related Clinical Factors Influencing One-Year Outcomes in Adult Patients after Orthotopic Heart Transplantation - A Single-Center Polish Experience
- Author
-
Kuczaj, A.A., primary, Warwas, S., additional, Król, B., additional, Hrapkowicz, T., additional, Śliwka, J., additional, Pawlak, S., additional, and Przybyłowski, P., additional
- Published
- 2023
- Full Text
- View/download PDF
5. (1372) - Toxic Milk- Should We Still be Afraid of Breastfeeding While on Tacrolimus Therapy: A Case Study
- Author
-
Danel, A., Warwas, S., Przybyłowski, P., Śliwka, J., Pawlak, S., Trzcińska, I., and Hrapkowicz, T.
- Published
- 2024
- Full Text
- View/download PDF
6. 1465Hybrid coronary revascularization in selected patients with multivessel disease - 5 year clinical outcomes of the prospective randomized pilot study
- Author
-
Tajstra, M, primary, Hrapkowicz, T, additional, Hawranek, M, additional, Filipiak, K, additional, Gierlotka, M, additional, Zembala, M, additional, Gasior, M, additional, and Zembala, M O, additional
- Published
- 2018
- Full Text
- View/download PDF
7. Right Ventricular Function in Patients With Left Ventricular Assist Device Support by Pulsatile Polvad MEV and Continuous-Flow Pumps Heartware and Heartmate II
- Author
-
Nadziakiewicz, P., primary, Borkowski, J., additional, Szygula-Jurkiewicz, B., additional, Niklewski, T., additional, Pacholewicz, J., additional, Zakliczynski, M., additional, Hrapkowicz, T., additional, and Zembala, M., additional
- Published
- 2016
- Full Text
- View/download PDF
8. Comparison of Mechanical Circulatory Support by the Use of Pulsatile Left Ventricular Assist Devices Polvad MEV and Continuous Flow Heart Ware and Heart Mate II in a Single-Center Experience
- Author
-
Nadziakiewicz, P., primary, Pacholewicz, J., additional, Zakliczynski, M., additional, Niklewski, T., additional, Borkowski, J., additional, Hrapkowicz, T., additional, and Zembala, M., additional
- Published
- 2016
- Full Text
- View/download PDF
9. Effects of Left Ventricular Assist Device Support on End-Organ Function in Patients With Heart Failure: Comparison of Pulsatile- and Continuous-Flow Support in a Single-Center Experience
- Author
-
Nadziakiewicz, P., primary, Szygula-Jurkiewicz, B., additional, Niklewski, T., additional, Pacholewicz, J., additional, Zakliczynski, M., additional, Borkowski, J., additional, Hrapkowicz, T., additional, and Zembala, M., additional
- Published
- 2016
- Full Text
- View/download PDF
10. Fractal Analysis of Heart Graft Acute Rejection Microscopic Images
- Author
-
Pijet, M., primary, Nozynski, J., additional, Konecka-Mrowka, D., additional, Zakliczynski, M., additional, Hrapkowicz, T., additional, and Zembala, M., additional
- Published
- 2014
- Full Text
- View/download PDF
11. (1372) - Toxic Milk- Should We Still be Afraid of Breastfeeding While on Tacrolimus Therapy: A Case Study.
- Author
-
Kuczaj, A., Danel, A., Warwas, S., Przybyłowski, P., Śliwka, J., Pawlak, S., Trzcińska, I., and Hrapkowicz, T.
- Subjects
- *
TACROLIMUS , *BREASTFEEDING , *GOAT milk - Published
- 2024
- Full Text
- View/download PDF
12. Hospital-To-Hospital Sharing of Patients with Cardiogenic Shock Bridged with Ecmella.
- Author
-
Kosiorowska, K., Bochenek, M., Bielicki, G., Zakliczyński, M., Hrapkowicz, T., Kuliczkowski, W., and Przybylski, R.
- Subjects
- *
HEART assist devices , *HEART failure , *CARDIOGENIC shock , *HEART transplantation , *TRANSPORTATION of patients , *HEART failure patients , *AIR travel , *MYOCARDIAL infarction - Abstract
For some patients with advanced heart failure, left ventricular assist devices or heart transplantation is crucial. In the case of an additionally developed cardiogenic shock, it is possible to bridge the surgery with the support of both ECMO and Impella, the so-called ECMELLA. Preoperative stabilization potentially improves surgical outcomes although an appropriate strategy has not yet been established. These patients must then be transferred to an LVAD / HTx facility. There are not many reports in the literature on the international and interhospital transport of patients in cardiogenic shock. We would like to present the cases of two ECMELLA assisted patients who were transported from distant centers in Europe and their subseqent clinical course. The first patient, a 27-year-old man with dilated cardiomyopathy, was admitted to a London hospital due to thrombus in the LV with peripheral acute embolism complicated with acuted kidney and liver dysfuncion. He was put on ECMELLA support. Due to mention of methamphetamine use in his history, he was disqualified from a transplant in the UK. The decision was made to transport the patient to our facility more than 1,000 km away, in order to be able to put him on the active waiting list for a transplant. On day 19 the ECMELLA system was replaced with left ventricular assist device, and on day 27 the patient was transplanted and discharged home another 4 weeks later. He remains clean, one year after the heart transplant. The second patient was a 50-year-old patient after extensive myocardial infarction that was admitted to the hospital in Norway where he subsequently had an ECMELLA implanted. Due to the extended waiting time for a transplant in Norway and unknown neurological status, the patient was consulted with our center and then transported nearly 3,000 km by air transport. Upon his arrival, he was implanted with a HMIII and was discharged 4 weeks later. He remains on the active waiting list for heart transplantation. Due to the small number of LVAD / HTx centers, the number of such interventions is significantly limited. In our abstract, we want to highlight the safe long-distance transport of patients with advanced heart failure. We also want to raise a discussion - Will organ transport sharing be replaced by patient sharing? [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Donor-Related Clinical Factors Influencing One-Year Outcomes in Adult Patients after Orthotopic Heart Transplantation - A Single-Center Polish Experience.
- Author
-
Kuczaj, A.A., Warwas, S., Król, B., Hrapkowicz, T., Śliwka, J., Pawlak, S., and Przybyłowski, P.
- Subjects
- *
HEART transplantation , *ARTIFICIAL blood circulation , *GRAFT rejection , *HEART transplant recipients , *CARDIAC arrest - Abstract
The study aimed to determine the influence of ischemia time, sudden cardiac arrest, and troponin levels in the donor on annual survival, cellular rejection, and functional parameters in adult heart transplant recipients The study population consisted of 258 (199 (77%) men) consecutive adult patients (pts) treated with orthotopic heart transplantation (OHT) between 2015 and 2020 in a single heart transplant center : The baseline characteristics of the recipient population were as follows: mean age at the time of OHT was 55 years (±12), ischemic etiology was present in 83 (32%), diabetes mellitus in 62 (24%), severe renal insufficiency in 13 (5%), obesity in 26 (10%), mechanical circulatory support (MCS) before OHT in 61 (23.64%) pts. A basic immunotherapy scheme consisted of tacrolimus used in 255 (99%) pts, cyclosporine in 3 (1%), everolimus in 42 (16%), and mycophenolate in 256 (99%) pts. The mean donor age equaled 38 (± 10) years. 57 (23%) donors had a sudden cardiac arrest (SCA). The mean donor troponin level was 53 (±142.26) ng/l, mean graft ischemic time was 165 (± 51) min. There were 39 (15.12%) cases of sex mismatch and 23 (8.91%) female-to-male transplantations. One-year acute cellular rejection index (ACRI) was: median = 0.077; Q1 = 0; Q3 = 0.154. LVEF in the first year: median = 56%; Q1 = 55%; Q3 = 60%. TAPSE in the first year: median = 13mm; Q1 = 12mm; Q3 = 15mm. Mortality in the first year equaled 25.58%. The troponin donor levels were significantly higher in donors who underwent SCA (20.0 ng/l vs 4.12 ng/l, p=0.006). However, median LVEF and median TAPSE in pts who received a heart from donors after SCA did not significantly differ from pts who received it from non-SCA donors (58% vs 55%, p= 0.095, 13mm vs 13mm, p= 0.83). There was no correlation between the ACRI and the graft ischemia time (R=-0.04, p=0.61), troponin level in donors, and ACRI (R=-0.02, p=0.80). In the population of the deceased in the first year after OHT, median donor troponin levels were 0.41 ng/l vs 5.28 ng/l in survivors; p=0.56, median ischemia time 168 min vs 160 min; p=0.24 Ischemia time, SCA, and troponin levels in accepted heart donors do not seem to influence the donor's annual survival, cellular rejection, and functional parameters in adult heart transplant recipients [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Temporal trends in in-hospital mortality of 7 628 patients with myocardial infarction complicated by cardiogenic shock treated in the years 2006-2021. An analysis from the SILCARD Database.
- Author
-
Trzeciak P, Tajstra M, Wojakowski W, Cieśla D, Kalarus Z, Milewski K, Hrapkowicz T, Mizia-Stec K, Smolka G, Nadolny K, Deja M, Kukulski T, Wilczek K, Kowalczyk J, Bochenek A, Przybyłowski P, Wita K, and Gąsior M
- Published
- 2024
- Full Text
- View/download PDF
15. Ultra-long term histopathological workup of an Amplatzer Muscular Septal Defect Occluders after surgical removal of the heart due to heart transplantation.
- Author
-
Białkowski J, Fiszer R, Hrapkowicz T, Pawlak S, Zdrzałek-Skiba A, Nożyński J, Skowronek R, and Szkutnik M
- Published
- 2024
- Full Text
- View/download PDF
16. Fibrin clot permeability (Ks) in patients on left ventricular assist device.
- Author
-
Kuczaj A, Skrzypek M, Hudzik B, Kaczmarski J, Pawlak S, Hrapkowicz T, and Przybyłowski P
- Subjects
- Humans, Middle Aged, Male, Female, Permeability, Blood Coagulation, Hemostasis, Heart-Assist Devices adverse effects, Fibrin metabolism, Heart Failure therapy, Heart Failure metabolism
- Abstract
Patients on left ventricular assist devices (LVAD) are prone to excessive hemostasis disturbances due to permanent contact of artificial pump surfaces with blood components. We aimed to investigate if fibrin clot permeability is altered in patients on long-term continuous-flow LVAD therapy and if the clot permeability is associated with clinical characteristics and adverse events. We investigated 85 end-stage heart failure patients (90.6% men, age 48.6-63.8 years) scheduled for continuous flow long-term LVAD support according to current clinical indications. The patients were assessed periodically: prior to LVAD implantation (T1), 3-6 months (T2) after LVAD implantation, 6-12 months after (T3) and then every 6 months. We tested the first three blood samples (T1-T3) and the last available blood sample (T4), but no longer than 5 years after LVAD implantation. We assessed hemostasis parameters (Activated Partial Thromboplastin Time (APTT) Prothrombin Time, Activated Partial Thromboplastin Time, Fibrinogen, D-dimer, Antithrombin, Thrombin Time, Factor VIII, and von Willebrand Factor, aspirin-induced platelet inhibition, adenosine-diphosphate test) changes during the study period. Fibrin Clot Permeability was evaluated using a pressure system and Permeability Coefficient (Ks) was calculated. We observed a decrease in fibrin clot permeability (Ks) between T1, T2, T3 and T4 time periods; P < 0.01 for each comparison. Fibrin clot permeability was negatively correlated with fibrinogen concentration: r = - 0.51, P < 0.001, factor VIII activity r = - 0.42, P < 0.001. There was no association of Ks with age, Left Ventricular Ejection Fraction (LVEF) and medications P > 0.001, however cumulative measurements in patients on aspirin showed shortening of Ks in this group P = 0.0123. Major adverse cardiac and cerebrovascular events (MACCE) occurred in 36.5% patients, bleeding events in 25.9%, Net Adverse Clinical Events (NACE) in 62.4%; 31.7% patients died, and 17.6% underwent transplantation. The transplantation was considered as the endpoint. Discrepancies in Ks were observed between patients with MACCE, bleeding, and NACE, and patients without adverse events. Ks showed a constant trend towards normalization (P < 0.01) only in patients without adverse events. Patients with advanced heart failure have disturbed clot structure. A trend towards normalization of the Ks values is associated with fewer thromboembolic and bleeding complications in this group of patients., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
17. Rupture of the ascending aorta 6 months after TAVI procedure caused by TAVI prosthesis.
- Author
-
Hirnle G, Kubik H, Tenczyński D, Kostro M, and Hrapkowicz T
- Subjects
- Aged, 80 and over, Humans, Male, Aorta diagnostic imaging, Aorta surgery, Computed Tomography Angiography, Heart Valve Prosthesis adverse effects, Postoperative Complications diagnostic imaging, Postoperative Complications etiology, Postoperative Complications surgery, Aortic Rupture diagnostic imaging, Aortic Rupture etiology, Aortic Rupture surgery, Aortic Valve Stenosis surgery, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement instrumentation
- Abstract
Background: Transcatheter aortic valve implantation (TAVI) is indicated for elderly patients who often have severe comorbidities and high operative risk. Despite many advantages, it carries the potential for both early and late complications. The literature reports mainly periprocedural problems. This case report describes a rare instance of ascending aortic rupture as a late complication following TAVI., Case Presentation: An 81-year-old male with severe aortic stenosis (AS) was a non-surgical patient due to a high operative risk (EuroSCORE II 14.08%) and comorbidities, including cardiovascular problems, chronic obstructive pulmonary disease, myelodysplastic syndrome. During the TAVI procedure Medtronic CoreValve™ Evolut™ R-26 was implanted via the right femoral artery. Postoperative period elapsed without complications and the patient was discharged home. Six months later, the patient was re-admitted to the hospital on an emergency basis and transferred directly to the operating room due to ascending aortic rupture (EuroSCORE II 53.20%, GERAADA score 64.9%). Computed tomography angiography (CTA) showed aortic rupture with a multiple fresh blood reservoirs and thrombus around the ascending aorta originating from the spot where the nitinol frame of the TAVI valve was attached to the native aorta. Supracoronary excision of the ascending aorta with implantation of a vascular graft (Intergard Woven Graft 34 mm) was performed, preserving the earlier implanted TAVI valve. On the 9th day after surgery the patient's general condition deteriorated, he suffered from circulatory and respiratory insufficiency. Furthermore, a gastrointestinal bleeding with the need for gastro-, and colonoscopy and multiple blood transfusions occurred. Patient developed urosepsis and acute renal failure with the need for hemodiafiltration. Despite intensive treatment, further deterioration of the medical condition of the patient. and finally the multiple organ failure was observed. Patient died on the 50th postoperative day., Conclusions: TAVI is a safe method of treating severe AS, especially recommended for non-surgical candidates. Rupture of the ascending aorta is a rare but serious complication of TAVI that usually occur during or shortly after the procedure. This case report highlights the importance of post-procedural monitoring for such TAVI complications, even in the late period following TAVI, and if such complications occur, taking the risk to perform a life-saving operation., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
18. Viral Myocarditis as a Factor Leading to the Development of Heart Failure Symptoms, Including the Role of Parvovirus B19 Infection-Systematic Review.
- Author
-
Krych S, Jęczmyk A, Jurkiewicz M, Żurek M, Jekiełek M, Kowalczyk P, Kramkowski K, and Hrapkowicz T
- Subjects
- Humans, Cardiomyopathy, Dilated virology, Cardiomyopathy, Dilated pathology, Myocarditis virology, Myocarditis etiology, Parvovirus B19, Human pathogenicity, Heart Failure virology, Heart Failure etiology, Parvoviridae Infections complications, Parvoviridae Infections virology
- Abstract
Myocarditis (MC) is defined as an immunological inflammatory reaction with various etiologies, clinical presentations and prognoses within the myocardium. Currently, parvovirus B19 (PVB19) has become the main factor leading to this disease, replacing the previously dominant viruses A and B. In the case of chronic heart failure with subsequent dilated cardiomyopathy, approximately 67% have a viral etiology, and most of them are the result of PVB19 infection. However, the analysis showed a correlation between PVB19 infection and the risk of developing inflammatory dilated cardiomyopathy (DCMi). PVB19 is detected in 23% of patients with DCMi. Chronic infection may also contribute to progressive left ventricular failure in patients with a history of MC. The above effect suggests the active replication of PVB19 only in heart biopsies with inflammation due to MC or DCMi. Moreover, the supply of IFN-β to suppress the active transcription of PVB19 accompanied by DCMi over a period of 6 months results in the normalization of NT-proBNP and an improvement in LVEF along with NYHA performance. The small number of reports on this topic and inaccuracies resulting from constantly conducted research and ongoing changes make it impossible to clearly answer the question of whether PVB19 is a factor inducing de novo MC and DCM or only accompanies the above conditions. However, large clinical cohort studies lead to the perception of PVB19 as a viral etiological agent capable of causing de novo MC together with DCMi.
- Published
- 2024
- Full Text
- View/download PDF
19. Gender Differences in Survival after Coronary Artery Bypass Grafting-13-Year Results from KROK Registry.
- Author
-
Hirnle G, Stankiewicz A, Mitrosz M, Aboul-Hassan SS, Deja M, Rogowski J, Cichoń R, Anisimowicz L, Bugajski P, Tobota Z, Maruszewski B, and Hrapkowicz T
- Abstract
The influence of gender on both early and long-term outcomes of coronary artery bypass grafting (CABG) is not clearly defined. Objectives: This study aimed to assess the impact of gender on early and long-term mortality after CABG using data from the KROK Registry. Methods: All 133,973 adult patients who underwent CABG in Poland between 1 January 2009 and 31 December 2019 were included in the Polish National Registry of Cardiac Surgical Procedures (KROK Registry). The study enrolled 90,541 patients: 68,401 men (75.55%) and 22,140 women (24.45%) who met the inclusion criteria. Then, 30-day mortality, 1-year mortality, and long-term mortality rates were compared. Results: Advanced age, higher Canadian Cardiovascular Society (CCS) and New York Heart Association (NYHA) grade, diabetes, hypercholesterolemia, arterial hypertension, body mass index BMI > 35 kg/m
2 , and renal failure, before the propensity matching, were more frequently observed in women. Women more frequently underwent urgent surgery, including single and double graft surgery, and off-pump CABG (OPCAB) ( p < 0.001). In propensity-matched groups, early mortality (30 days) was significantly higher in women (3.4% versus 2.8%, p < 0.001). The annual mortality remained higher in this group (6.6% versus 6.0%, p = 0.025). However, long-term mortality differed significantly between the groups and was higher in the male group (33.0% men versus 28.8% women, p < 0.001). Conclusions: There are no apparent differences in long-term mortality between the two sexes in the entire population. In propensity-matched patients, early mortality was lower for men, but the long-term survival was found to be better in women.- Published
- 2024
- Full Text
- View/download PDF
20. Predictors of renal replacement therapy following isolated coronary artery surgery - a retrospective case controlled study.
- Author
-
Krauchuk A, Hrapkowicz T, Suwalski P, Perek B, Jasiński M, Hirnle T, Nadziakiewicz P, and Knapik P
- Abstract
Objectives: Severe acute kidney injury (AKI) requiring postoperative renal replacement therapy (RRT) is associated with increased morbidity and mortality rate following cardiac surgery. Our study was aimed to analyze patients requiring postoperative RRT in a population undergoing isolated coronary artery surgery., Methods: Following exclusions, we analyzed 124,944 consecutive patients in the Polish National Registry of Cardiac Surgical Procedures (KROK Registry), scheduled for isolated coronary artery surgery between January 2010 and December 2019. Patients who underwent preoperative chronic dialysis were excluded from the study. Data of patients requiring postoperative RRT and patients without postoperative RRT were compared., Results: In the analyzed population, 1,668 patients (1.3%) developed AKI requiring RRT. In-hospital mortality among patients with and without postoperative RRT were 40.1% and 1.6%, respectively (P<0.001). Patients requiring postoperative RRT had significantly more preoperative co-morbidities and more frequent postoperative complications. Preoperative chronic renal failure and cardiogenic shock were the two most prominent independent risk factors for postoperative RRT in these patients (OR: 5.0, 95%CI: 3.9-6.4, P<0.001 and OR: 3.9, 95%CI: 2.8-5.6, P<0.001, respectively)., Conclusion: Severe acute kidney injury (AKI) requiring postoperative RRT dramatically increases in-hospital mortality and is associated with the development of serious postoperative complications. The need for postoperative RRT is clearly associated with the presence of preoperative co-morbidities. Preoperative chronic renal failure and cardiogenic shock were particularly related with the development of this complication., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
21. Graphene Oxide Significantly Modifies Cardiac Parameters and Coronary Endothelial Reactivity in Healthy and Hypertensive Rat Hearts Ex Vivo .
- Author
-
Krasoń MZ, Paradowska A, Boncel S, Lejawa M, Fronczek M, Śliwka J, Nożyński J, Bogus P, Hrapkowicz T, Czamara K, Kaczor A, and Radomski MW
- Abstract
Interactions of graphene oxide (GO) with an ex vivo rat heart and its coronary vessels have not been studied yet. Moreover, the conflicting data on the "structure-properties" relationships do not allow for biomedical applications of GO. Herein, we study the impact of GO on the ex vivo isolated rat heart, normotensive and hypertensive, under the working heart and the constant-pressure perfusion (Langendorff) regimes. Four structural GO variants of the following initial morphology were used: few-layer (below 10-layer) GO1, O < 49%; predominantly single-layer GO2, O = 41-50%; 15-20-layer GO3, O < 11%; and few-layer (below 10-layer) NH
4 + -functionalized GO4, O < 44%, N = 3-6%. The aqueous GO dispersions, sonicated and stabilized with bovine serum albumin in Krebs-Henseleit-like solution-uniformized in terms of the particle size-were eventually size-monodisperse as revealed by dynamic light scattering. To study the cardiotoxicity mechanisms of GO, histopathology, Raman spectroscopy, analysis of cardiac parameters (coronary and aortic flows, heart rate, aortic pressure), and nitric oxide (NO-)-dependent coronary flow response to bradykinin (blood-vessel-vasodilator) were used. GO1 (10 mg/L) exerted no effects on cardiac function and preserved an increase in coronary flow in response to bradykinin. GO2 (10 mg/L) reduced coronary flow, aortic pressure in normotensive hearts, and coronary flow in hypertensive hearts, and intensified the response to bradykinin in normal hearts. GO3 (10 mg/L) reduced all parameters in hypertensive hearts and coronary response to bradykinin in normal hearts. At higher concentrations (normotensive hearts, 30 mg/L), the coronary response to bradykinin was blocked. GO4 (10 mg/L) reduced the coronary flow in normal hearts, while for hypertensive hearts, all parameters, except the coronary flow, were reduced and the coronary response to bradykinin was blocked. The results showed that a low number of GO layers and high O-content were safer for normal and hypertensive rat hearts. Hypertensive hearts deteriorated easier upon perfusion with low-O-content GOs. Our findings support the necessity of strict control over the GO structure during organ perfusion and indicate the urgent need for personalized medicine in biomedical applications of GO., Competing Interests: The authors declare no competing financial interest., (© 2024 The Authors. Published by American Chemical Society.)- Published
- 2024
- Full Text
- View/download PDF
22. Lung Transplantation in Patients With Pulmonary Hypertension With Extracorporeal Membrane Oxygenation (ECMO) Support: 5-Year Experience.
- Author
-
Stącel T, Kegler K, Mędrala A, Sybila P, Ochman M, Nęcki M, Pasek P, Gummenyi I, Pióro A, Przybyłowski P, Hrapkowicz T, and Urlik M
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Adult, Treatment Outcome, Extracorporeal Membrane Oxygenation, Lung Transplantation, Hypertension, Pulmonary surgery, Hypertension, Pulmonary therapy
- Abstract
Lung transplantation (LTx) is the only treatment option of patients (pts) with pulmo-nary hypertension (PH) when pharmacologic treatment is unsatisfactory. ECMO is essential during LTx in every patient with pulmonary arterial hypertension and in most patients with sec-ondary PH. This is a retrospective, single-center study comparing LTx outcomes in patients with and without PH covering a 5-year experience. In the years 2018-2023, 219 LTx were performed, of which 56 (25.6%) with ECMO support, among which PH was diagnosed in 34pts (60.7%) in WHO groups 1,3,4: 19pts, 14pts. and 1pt respectively. The veno-arterial type of ECMO was used in patients with PH as intraoperative support (n = 34; 100%). The early (30-day) and long-term survival (1 year) of patients with and without PH did not differ statistically: 91.2% (95% CI: 82.1%-100%) vs. 77.3% (95% CI: 82.1%-100%)(P = .48) and 53.0% (95% CI: 36.6%-76.7 %) vs. 41.3% (95%CI: 23.1-74.0) (P = .48) respectively and the median hospitalization time from ECMO weaning to dis-charge was also comparable: 31 days (Q1-Q3: 21-40; IQR 20) vs. 28 days (Q1-Q3: 24-42; IQR :18) (P = .99). Patients with or without PH undergoing LTx with ECMO have comparable survival and hospital stay outcomes despite being the most challenging of all lung diseases treated with lung transplantation., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
23. Assessment of Selected Parameters of Heart Donors and Recipients and Their Impact on the Transplantation Result.
- Author
-
Antończyk R, Kuczaj A, Pawlak S, Śliwka J, Przybyłowski P, and Hrapkowicz T
- Subjects
- Humans, Female, Adult, Male, Middle Aged, Treatment Outcome, Young Adult, Retrospective Studies, Heart Transplantation adverse effects, Heart Transplantation mortality, Tissue Donors
- Abstract
Objective: To evaluate the impact of heart donors and recipients parameters on the outcomes after orthotopic heart transplantation (OHT)., Methodology: Two hundred fifteen patients who underwent OHT from 2020 to 2023 were analyzed., Results: Average donors age 36.3 (±13.1) years, 74 women (34.42%), BMI 25.3 (±4.99), Na+ concentration 153.7 (±11.8) mmol/L. Mean intraventricular septum thickness 10.0 (±2.2) mm, left ventricular end-diastolic diameter 44.3 (±6) mm, ejection fraction 60.3 (±7.92) %. Median procalcitonin was 0.6 ng/mL. Levonor was used in 75.8%, Empressin in 4.2%, Dopamine in 5.1%, Dobutamine in 3.7%, and Adrenaline in 3.7% of donors. The most common cause of death: intracranial injury (34.42%). Cardiopulmonary resuscitation occurred in 34%, alcoholism in 20.9%, nicotinism in 16.3%, and drug addiction in 7.4% of donors. Mean aortic cross-clamping time was 200.3 (±48.8) minutes. Intra-aortic balloon pump (IABP) after OHT required 6.1%, extra corporeal membrane oxygenation (ECMO) 6.1%, and renal dialysis 36% of recipients. The 1-year mortality rate was 19.1%. Death after OHT correlated with: longer aortic cross-clamping time (207.6 vs 198.59 minutes, P = .292), longer extracorporeal circulation time (196.3 vs 186.47 minutes, P = .335), lower Empressin dose (median 0.01 vs 0.02 j.m/min, P = .03) in donors, longer postoperative mechanical ventilation (mean 101.46 vs 23.09 hours, P = .001), more frequent dialysis, IABP or ECMO (P = .001) and older age of the recipient (51.2 vs 44.8 years, P = .014). Previous cardiac surgery or any surgical intervention after transplantation significantly influenced mortality. The remaining donor factors had no impact on the OHT result., Conclusions: Identification of risk factors in the donor and recipient may improve treatment outcomes after OHT., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
24. Impact of Prolonged Cold Ischemia Time on Long-Term Survival in Lung Transplant Recipients.
- Author
-
Ochman M, Zawadzki F, Galle D, and Hrapkowicz T
- Subjects
- Humans, Female, Retrospective Studies, Male, Middle Aged, Adult, Time Factors, Risk Factors, Lung Transplantation mortality, Cold Ischemia
- Abstract
Background: Cold ischemia time (CIT) influences short- and long-term outcomes in lung transplant recipients. Most studies proved that prolonged CIT causes increased mortality. This study aimed to investigate the impact of prolonged CIT on patient survival time after lung transplantation (LTx)., Methods: The retrospective study group consisted of 139 patients who underwent double LTx in a single center between January 2018 and August 2022. Prolonged ischemic time (PIT) was defined as total ischemic time >6 hours and divided into smaller time intervals according to increasing PIT (6-8, 8-10, 10-12, >12 hours). The assessed outcomes were 1- and 4-year survival., Results: Among the study group, PIT was observed in 98% (n = 137), and its average value was 10.33 hours. The prolonged CIT of 6 to 8 hours occurred in 10% (n = 14), 8 to 10 hours in 34% (n = 47), 10 to 12 hours in 36% (n = 49), and >12 hours in 20% (n = 27). In a comparison of 1-year survival between the PIT 6- to 10-hour group and the >10-hour arm (88% vs 78%), the difference was not statistically significant (P > .05)., Conclusion: PIT is a risk factor for reduced long-term survival in LTx recipients. Increasing PIT may be associated with higher mortality at 1 and 4 years. All efforts to reduce the duration of ischemic time can benefit patient survival after LTx., Competing Interests: Declaration of competing interest All the authors declare no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. Utility of 64-Slice Coronary Computed Tomography Angiography in Heart Transplant Recipients.
- Author
-
Kuczaj A, Pawlak S, Głowacki J, Antończyk R, Śliwka J, Przybyłowski P, and Hrapkowicz T
- Subjects
- Humans, Female, Middle Aged, Male, Adult, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease surgery, Aged, Heart Transplantation adverse effects, Computed Tomography Angiography, Coronary Angiography
- Abstract
Background: Graft vasculopathy is a leading cause of death after heart transplantation (HTx). Diagnosing cardiac allograft vasculopathy (CAV) within this patient group poses significant challenges. This study aimed to evaluate the safety and efficacy of coronary computed tomographic angiography (CCTA) in patients after HTx., Methods: We enrolled 107 consecutive HTx recipients (26 women, mean age 50 ± 17 years); all were ≥3 years post-HTx with minimal or no evidence of CAV in a prior coronary angiography performed a minimum of 2 years before the current examination. The inclusion criteria comprised an estimated glomerular filtration rate (eGFR) of ≥30, absence of new heart failure symptoms, and no contraindications to iodine contrast or CT scans. All patients underwent a 64-slice CCTA. In cases of minimal or no changes, noninvasive follow-up examinations were conducted. Significant changes in CT prompted additional coronary angiography., Results: Of the enrolled participants, 9 exhibited minimal changes; 98 displayed no changes in coronary angiography. The median time since transplant was 7 years, with IQR of 4 to 11.25 years. Significant changes were excluded in 98 patients. Among the 9 patients with suspected significant CAV, significant changes were confirmed in 8 patients, resulting in percutaneous transluminal coronary angioplasty (PTCA) performed in 6. One patient from this group died shortly after PTCA. No cardiovascular incidents were observed within the remaining group. The median follow-up period was 539 (IQR = 289-654 days). The mean left ventricular ejection fraction at follow-up was 58% ± 5% compared with 58% ± 4% at baseline. At follow-up, the mean eGFR was 64 ± 18 mL/kg/1.73 m
2 compared with the baseline value of 67.2 mL/kg/1.73 m2 ., Conclusions: CCTA appears to offer a secure and efficient means of assessment in HTx recipients., Competing Interests: Declaration of competing interest All the authors declare no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
26. Lung Transplantation in Patients With Systemic Scleroderma-Description of the First Consecutive Cases in Poland: Case Series Report and a Short Literature Review.
- Author
-
Stącel T, Sybila P, Mędrala A, Ochman M, Nęcki M, Pasek P, Kegler K, Przybyłowski P, Hrapkowicz T, Borowik D, and Urlik M
- Subjects
- Humans, Female, Middle Aged, Male, Adult, Poland, Hypertension, Pulmonary surgery, Lung Diseases, Interstitial surgery, Respiratory Insufficiency etiology, Respiratory Insufficiency surgery, Treatment Outcome, Pulmonary Fibrosis surgery, Lung Transplantation, Scleroderma, Systemic surgery, Scleroderma, Systemic complications
- Abstract
Pulmonary complications of systemic scleroderma (SSc), such as interstitial lung disease and pulmonary hypertension (PH), are responsible for up to 60% of deaths among patients. For many years, most centers considered SSc a contraindication to lung transplantation (LTx); however, recent publications show that appropriately selected SSc candidates for LTx give results comparable to patients with idiopathic PH or idiopathic pulmonary fibrosis. This paper presents the cases of a 60-year-old male patient (patient 1) and a 42-year-old female patient (patient 2) diagnosed with SSc in 2019 and 2013, respectively. In both patients, interstitial-fibrotic changes in the lungs leading to respiratory failure were confirmed by high-resolution computed tomography as well as pulmonary hypertension (WHO group 3), which was also diagnosed during right heart catheterization. In both cases, despite pharmacotherapy, pulmonary fibrosis progressed, leading to severe respiratory failure. The patients were referred for LTx qualification. LTx was possible to consider in patients due to the lack of significant changes in other internal organs. Double LTx was successfully performed in both patients (patient 1-July 19, 2022; patient 2-September 14, 2022). They were discharged from the hospital in good condition on the 22nd and 20th postoperative day, respectively. LTx is a last-chance therapy that saves lives among patients with extreme respiratory failure in the course of SSc. It prolongs and improves the quality of life. The selection of appropriate patients is key to the success of the procedure., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. Systemic Sclerosis as a Challenge for Heart Transplantation: A Case Report.
- Author
-
Śliwka J, Pawlak S, Kuczaj A, Herdyńska-Wąs M, Przybyłowski P, and Hrapkowicz T
- Subjects
- Humans, Adult, Male, Heart Failure surgery, Heart Failure etiology, Immunosuppressive Agents therapeutic use, Treatment Outcome, Waiting Lists, Heart Transplantation, Scleroderma, Systemic complications
- Abstract
Objective: To assess the principles of qualification and the range of organ transplantation in a patient with diagnosis of system sclerosis with pulmonary manifestation and severe myocardial insufficiency., Methods: We present the case of a 43-year-old patient with confirmed systemic sclerosis with pulmonary manifestations and biventricular heart insufficiency after disease exacerbation and sudden cardiac arrest in the pulseless electrical activity (PEA) mechanism with effective resuscitation, with increasing shortness of breath and the need for inotropes and levosimendan infusion without a significant improvement in his general status. Owing to the diagnosis of a systemic disease with no option for pharmacologic or any other treatment for heart failure, he was reevaluated and put on an urgent waiting list for isolated heart transplantation. After 7 days, heart transplantation was performed. Given the risk of disease progression and the possibility of future lung transplantation, the pleural cavities were untouched. The standard immunosuppression protocol was followed with the use of rabbit antithymocyte globulin., Results: The patient was extubated at 24 hours after heart transplantation. The results of endomyocardial biopsies performed during the hospital stay and at a 6-month follow-up were negative. The patient was discharged to home after 22 days of an uneventful hospital stay., Conclusions: Scleroderma as an autoimmunologic disease remains a challenge for the transplantation team as a possible progressive multiorgan insufficiency requiring qualification for organ transplantation. The course of the disease varies depending on the form of systemic sclerosis. Careful assessment, qualification, and determination of appropriate preprocedure and postprocedure immunosuppressive treatment are essential to an uncomplicated course of treatment., Competing Interests: Declaration of competing interest All the authors declare no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
28. Kidney Transplantation as a Treatment Option of Chronic Renal Failure Among Lung Transplant Recipients: A Single-Center Experience.
- Author
-
Ochman M, Zawadzki F, Galle D, Kowal A, Królikowska M, Salman J, and Hrapkowicz T
- Subjects
- Humans, Retrospective Studies, Male, Adult, Female, Middle Aged, Young Adult, Treatment Outcome, Lung Transplantation adverse effects, Kidney Transplantation adverse effects, Kidney Failure, Chronic surgery
- Abstract
Introduction: Chronic renal failure is one of the most common complications after solid organ transplantation. It is associated with multiple pre-, peri-, and post-transplant factors. In some patients, the available methods of conservative treatment are insufficient and kidney transplantation (KTx) is necessary. The aim of this study was to present our experience in the treatment of renal failure by KTx after lung transplantation (LTx)., Methods: Our study is a single-center retrospective review of clinical data of all 7 LTx recipients who underwent a KTx between the years 2013 and 2021. Patients' clinical condition, pulmonary function, renal function, and survival were examined., Results: There were a total of 7 patients with medium age 36 years (±15). In 3 patients, the period of time from LTx to KTx was less than 3 years, and in 4 of them less than 13 years. Dialysis therapy was required in 4 patients. One patient had pre-LTx renal disease, while 6 patients had renal dysfunction related to post-transplant factors, including the use of calcineurin inhibitors., Conclusions: Renal protection is a very important aspect among LTx recipients; therefore, physicians must show a holistic and individual approach to patients and minimize exposure to nephrotoxic medication. Patients at high risk of developing chronic renal failure should be identified and, if required, renal replacement therapy should be initiated, including KTx., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. First Successful Pregnancy After Lung Transplantation in Poland-Case Report.
- Author
-
Jabiry-Zieniewicz Z, Ochman M, Galle D, Królikowska M, Kowal A, Ludwin A, Mucha K, Jaworska I, Urlik M, Stącel T, and Hrapkowicz T
- Subjects
- Humans, Female, Pregnancy, Young Adult, Immunosuppressive Agents therapeutic use, Immunosuppressive Agents adverse effects, Poland, Cesarean Section, Pregnancy Complications surgery, Pregnancy Outcome, Lung Transplantation, Cystic Fibrosis surgery
- Abstract
Introduction: Lung transplantation is well-established treatment for patients with advanced lung dysfunction in cystic fibrosis (CF). Pregnancy in CF lung transplant recipients is feasible, although it still remains challenging for even professionals and demands a multidisciplinary approach., Case Report: We report the case of pregnancy in a 22-year-old woman after lung transplantation (LTx) due to end-stage respiratory failure in the course of CF. The interval from transplant to conception was 2.5 years. In 2019, orthotopic LTx was performed and a 3-drug immunosuppressive scheme was used-tacrolimus, mycophenolate mofetil, and prednisolone. There were no complications in the postoperative course. In April 2022, the patient was confirmed pregnant. All fetotoxic or teratogenic drugs were discontinued. Throughout the whole pregnancy, the patient was regularly monitored in the transplant and obstetrics centers. Due to the vaginal bleeding and irregular contractions at the 33 weeks of pregnancy, the course of steroids was administered. At 38 weeks and 5 days of gestation, she presented premature rupture of membranes. The caesarean section was performed because of breech presentation of the fetus. A live, term daughter was born and according to the screening test she does not have CF. Currently, 12 months after the delivery, the mother's lung function is good., Conclusions: Getting pregnant and having a safe pregnancy after LTx is possible, but it requires a specialized and individual approach. The patient should be well informed about possible complications and risks including graft failure. The patient's attitude and her cooperation with doctors play a major role., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
30. Pediatric Heart Transplantation in the Context of Severe Pulmonary Hypertension Secondary to Restrictive Cardiomyopathy-Case Report.
- Author
-
Pawlak S, Śliwka J, Kwiatkowska J, Wierzyk A, Kuczaj A, Przybyłowski P, and Hrapkowicz T
- Subjects
- Humans, Female, Child, Heart Transplantation, Cardiomyopathy, Restrictive surgery, Hypertension, Pulmonary surgery, Hypertension, Pulmonary etiology, Hypertension, Pulmonary physiopathology
- Abstract
The aim of this study is to analyze the feasibility of performing an isolated heart transplant in patients with severe pulmonary hypertension as a result of restrictive cardiomyopathy. The results present the clinical course from the diagnosis of restrictive cardiomyopathy at the age of 2 until the heart transplant at 8 years old. Initially, the patient was considered for multiorgan transplantation, heart and lungs, due to extremely high pulmonary resistance. However, due to the prolonged waiting period for a donor and the worsening condition of the child, a decision was made to perforate the atrial septum with the implantation of an atrial flow regulator system. After conducting control hemodynamic measurements, the qualification was changed to an isolated heart transplant, accepting the high operative risk associated with the still elevated pulmonary resistance index of 4.9 Wood units. This study describes the medical problems that occurred during postoperative treatment. The patient underwent an orthotopic heart transplant in her eighth year of life. Postsurgery, complications were observed, including generalized seizures and heart transplant rejection reaction. Immunosuppressive therapies were applied, and efforts were made to combat anemia and electrolyte disorders. While the cardiovascular system and heart parameters improved, there were some difficulties in controlling heart rhythm and stabilizing electrolyte levels., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
31. Pediatric Lung Transplantations: New Possibilities and Challenges in Treatment of Children With End-Stage Respiratory Failure.
- Author
-
Ochman M, Galle D, Goryczka A, Gałeczka-Turkiewicz A, Zawadzki F, Chorąży K, Stącel T, Urlik M, and Hrapkowicz T
- Subjects
- Humans, Child, Retrospective Studies, Male, Adolescent, Female, Cystic Fibrosis surgery, Treatment Outcome, Reoperation, Lung Transplantation, Respiratory Insufficiency surgery, Respiratory Insufficiency etiology
- Abstract
Introduction: Lung transplantation (LTx) is the last treatment option for children with end-stage respiratory failure. According to the literature, cystic fibrosis remains the most common cause of pediatric LTx. The study aimed to assess the characteristics of pediatric LTx recipients as well as the outcomes of the transplantation., Methods: Our study is a single-center retrospective review of clinical data of all 11 patients who underwent a LTx before the age of 18 years between the years 2016 and 2020. Medical records were examined for patients' characteristics, general treatment, and complications., Results: There were a total of 11 patients (8 males) with a median age 14.5 years (range: 11-17). The primary diseases that led to LTx were: cystic fibrosis in 8 patients (72.73%), hereditary hemorrhagic telangiectasia in 2 patients (18.18%), and idiopathic pulmonary arterial hypertension in 1 patient (9.09%). Median period from qualification to LTx was 235.55 days (range: 11-748). Two patients (18.18%) underwent lung retransplantation after 3 and 5 years. One patient passed away 10 months after surgery due to noncompliance., Conclusions: Pediatric lung transplantation is less common than lung transplantation in adults. It also differs in fields of donors accessibility, stronger immune system response and noncompliance that may lead to graft failure., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
32. Candida tropicalis endocarditis on the aortic valve with coexisting meningitis in a patient with multiple risk factors - What to do?
- Author
-
Hirnle G, Kapałka M, Krawiec M, and Hrapkowicz T
- Abstract
A 65-year-old female patient with Candida tropicalis infective endocarditis on the aortic valve underwent aortic valve replacement. In the postoperative period a head computer tomography revealed a left temporal arachnoid cyst, diagnosed as fungal meningitis. We outline a successful treatment approach for this high-risk patient., Competing Interests: All authors of this paper declare that the case report has not been previously published in print or electronic form, is not under consideration by another editorial board, and there are no ethical issues or conflicts of interest. All authors declare no conflict of interest regarding this manuscript., (© 2024 The Authors. Published by Elsevier Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
33. Single versus multiple arterial coronary artery bypass grafting in men and women: results from Polish National Registry of Cardiac Surgery Procedures.
- Author
-
Aboul-Hassan SS, Hirnle G, Perek B, Jemielity M, Hirnle T, Brykczynski M, Deja M, Rogowski J, Cisowski M, Krejca M, Anisimowicz L, Widenka K, Gerber W, Pacholewicz J, Bugajski P, Stepinski P, Maruszewski BJ, Cichon R, and Hrapkowicz T
- Subjects
- Humans, Male, Female, Aged, Poland, Middle Aged, Sex Factors, Saphenous Vein transplantation, Propensity Score, Retrospective Studies, Coronary Artery Bypass mortality, Coronary Artery Bypass statistics & numerical data, Coronary Artery Bypass methods, Registries, Coronary Artery Disease surgery, Coronary Artery Disease mortality
- Abstract
Background: The objective of this multicenter study aimed to investigate the impact of sex on long-term survival among patients with multivessel coronary artery disease undergoing coronary artery bypass grafting (CABG) using multiple arterial grafting (MAG) or a single artery with saphenous vein grafts., Materials and Methods: Data were obtained from the Polish National Registry of Cardiac Surgery Procedures database. This study included 81 136 patients who underwent CABG for multivessel disease between January 2012 and December 2020 (22.9 were women and 77.1% were men). MAG was performed in 8.3 and 11.7% of female and male patients, respectively. A 1:1 propensity score (PS)-matching was performed. Long-term mortality was compared between matched groups of men and women. Subgroup analyses of patients aged <70 and ≥70 years, with an ejection fraction (EF) >40% and ≤40%, and with and without diabetes, obesity, peripheral artery disease (PAD), or chronic lung disease (CLD) were performed separately in women and men., Results: MAG was associated with lower long-term mortality than saphenous vein grafts in 1528 PS-matched female pairs [hazard ratio (HR): 0.74; 95% CI: 0.59-0.92; P =0.007) and 7283 PS-matched male pairs (HR: 0.80; 95% CI: 0.72-0.88; P <0.001). Subgroup analyses confirmed the results among female patients aged <70 years, with diabetes and EF >40%, and without PAD or CLD, and of male patients aged <70 and ≥70 years; with EF >40%; with or without diabetes, obesity, or PAD; and without CLD., Conclusions: In patients undergoing CABG, MAG was associated with significantly improved survival in both sexes. The long-term benefits of MAG observed across subgroups of men and women support the consideration of a multiarterial revascularization strategy for a broader spectrum of patients., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
34. Thyroid Dysfunction in Advanced Heart Failure Patients and Its Correlation with Amiodarone Therapy: A Two-Year Study.
- Author
-
Kuczaj A, Warwas S, Danel A, Przybyłowski P, and Hrapkowicz T
- Abstract
(1) Background: Advanced heart failure often accompanies ventricular arrhythmias, necessitating antiarrhythmic therapies. Amiodarone, commonly used for this purpose, may induce thyroid dysfunction due to its high iodine content. However, the prevalence and correlation of thyroid dysfunction with amiodarone in end-stage heart failure patients remain unclear. Aim: This study aimed to evaluate the prevalence and types of thyroid dysfunction and their association with amiodarone among 200 patients diagnosed with advanced heart failure eligible for transplantation. (2) Methods: Consecutively enrolled patients received treatment following the European Society of Cardiology guidelines and were followed-up for two years. Ventricular arrhythmias affected 58.5% of the cohort, with 24.5% receiving amiodarone therapy. (3) Results: Thyroid metabolism dysfunction was evident in 61 patients, notably overrepresented in women ( p = 0.0028). Hyperthyroidism (34 patients) and hypothyroidism (27 patients) were observed, with a significant amiodarone-related correlation. Despite this, thyroid dysfunction was not associated with increased mortality among the studied group. (4) Conclusions: Thyroid dysfunction is prevalent in advanced heart failure patients, with a notable proportion linked to amiodarone. However, its presence does not correspond to higher mortality rates. Understanding these associations is crucial for effective management in this patient population. Further exploration is warranted to refine approaches to thyroid dysfunction in refractory heart failure.
- Published
- 2024
- Full Text
- View/download PDF
35. Inflammatory response induction as a result of BioGlue adhesive application in cardiac surgery - a review of the literature.
- Author
-
Furgoł T, Antończyk R, Miciak M, Jezierzański M, Smreczak M, Gigoń K, Fogiel O, Ratajczak M, and Hrapkowicz T
- Abstract
BioGlue is one of the best-known substances used as a tissue adhesive during surgical procedures, especially in cardiac surgery. Inappropriate use of BioGlue can result in inflammation in both the heart and adjacent tissues after its intraoperative application. Inflammation caused by BioGlue in cardiac surgery is a topic that has been discussed by numerous authors in scientific studies, meta-analyses and evaluations of this tissue adhesive. However, there is a lack of collected knowledge on this subject in a single concise article. The purpose of this paper is to review the current medical knowledge on the use of BioGlue in cardiac surgery versus the induction of an inflammatory response. Our paper discusses the details of this problem according to the most recent scientific reports., Competing Interests: The authors report no conflict of interest., (Copyright: © 2024 Polish Society of Cardiothoracic Surgeons (Polskie Towarzystwo KardioTorakochirurgów) and the editors of the Polish Journal of Cardio-Thoracic Surgery (Kardiochirurgia i Torakochirurgia Polska).)
- Published
- 2024
- Full Text
- View/download PDF
36. Zero-contrast TAVI: Novel alternative for challenging patient population.
- Author
-
Pyka Ł, Wilczek K, Kwiecień A, Niklewski T, Hrapkowicz T, and Gąsior M
- Subjects
- Humans, Male, Aged, Aged, 80 and over, Female, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis surgery
- Published
- 2024
- Full Text
- View/download PDF
37. Removal of the intra-aortic balloon pump: Why and in what way? Author's reply.
- Author
-
Rychter J and Hrapkowicz T
- Subjects
- Humans, Device Removal methods, Intra-Aortic Balloon Pumping
- Published
- 2024
- Full Text
- View/download PDF
38. Initial experience of intra-aortic balloon pump removal using Angio-Seal.
- Author
-
Rychter J, Jakimowicz K, Jaźwiec T, Pakuła R, Aidibi A, Bratkowski W, Pacholewicz J, and Hrapkowicz T
- Subjects
- Humans, Male, Aged, Female, Middle Aged, Intra-Aortic Balloon Pumping, Device Removal methods
- Published
- 2024
- Full Text
- View/download PDF
39. Management of patients with myocardial infarction complicated by cardiogenic shock: Data from a comprehensive all-comer administrative database covering a population of 4.4 million.
- Author
-
Gąsior M, Tajstra M, Cieśla D, Hrapkowicz T, Nadolny K, Wita K, Smolka G, Milewski K, Wojakowski W, Mizia-Stec K, Kalarus Z, and Trzeciak P
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Databases, Factual, Aged, 80 and over, Shock, Cardiogenic therapy, Shock, Cardiogenic etiology, Myocardial Infarction complications
- Published
- 2024
- Full Text
- View/download PDF
40. Current practice of care for adolescent and adult patients after Fontan surgery in Poland: Heart transplantation.
- Author
-
Białkowski J, Przybyłowski P, Hrapkowicz T, and Pawlak S
- Subjects
- Adult, Humans, Adolescent, Poland, Retrospective Studies, Heart Transplantation, Fontan Procedure, Heart Defects, Congenital surgery
- Published
- 2024
- Full Text
- View/download PDF
41. Torque Teno Virus (TTV)-A Potential Marker of Immunocompetence in Solid Organ Recipients.
- Author
-
Kuczaj A, Przybyłowski P, and Hrapkowicz T
- Subjects
- Humans, Viral Load, Immunosuppression Therapy, DNA, Viral, Immunocompetence, Torque teno virus genetics, Organ Transplantation adverse effects, DNA Virus Infections
- Abstract
Torque Teno Virus (TTV), first discovered in 1997, is a non-pathogenic, highly prevalent virus with a notable presence in the human virome. TTV has garnered attention as a potential indicator of immunocompetence in recipients of solid organ transplants. In this review, we discuss the role of TTV as a potential marker for immunosuppression optimization, prediction of graft rejection, and as an indicator of opportunistic infections. We discuss TTV's behavior over the course of time after transplantation, TTV's implications in different immunosuppressive regimens, and potential utility in vaccinations. The review synthetizes findings from various studies depicting its potential clinical utility for future personalized patient care.
- Published
- 2023
- Full Text
- View/download PDF
42. Comparison of outcomes in patients with severe aortic stenosis treated with small and large Medtronic Evolut R and Evolut PRO self-expandable prosthetic valves.
- Author
-
Wilczek K, Chodór P, Harpula J, Hrapkowicz T, Włoch Ł, Chodór-Rozwadowska K, Honisz G, Gąsior M, and Kalarus Z
- Abstract
Introduction: Indications for transcatheter aortic valve implantation (TAVI) continue to expand. Very often TAVI must be done in large annuli. Implantation of the bigger prostheses is often associated with more procedural problems, which may affect the outcomes., Aim: To compare the outcomes of TAVI procedures using the self-expandable Medtronic Evolut R 34 with the smaller Evolut R or Evolut Pro 23, 26 or 29., Material and Methods: We analysed 87 patients who received self-expandable Medtronic Evolut R and Pro valves. Group I consisted of 59 (67.81%) patients with Evolut 23, 26 or 29, and group II consisted of 28 (32.18%) patients who received an Evolut 34 valve., Results: EuroSCORE II was 5.59 in group I vs 7.87 in group II ( p = 0.02). The oversizing rate was higher in group II: 24.1% vs. 18.5% ( p < 0.001). The procedure and fluoroscopy times were longer in group II: 209 vs. 187 min ( p = 0.03), 44 vs. 27 min ( p = 0.01). Moderate paravalvular leak was found more frequently in group II: 5 v 1 ( p = 0.04). There was less device success in group II: 22 (78.57%) vs. 57 (96.6%) ( p = 0.05). Early safety criteria were similar in both groups: 52 (88.1%) and 24 (92.3%) ( p = 0.56). 30-day mortality was similar: 4 (6.7%) vs. 0 in group I and II respectively ( p = 0.16)., Conclusions: TAVI procedures in patients requiring an Evolut R 34 prosthesis are more challenging than in those who need smaller valves. Paravalvular leaks are more frequently observed after TAVI with Evolut R 34, which results in lower device success., Competing Interests: The authors declare no conflict of interest., (Copyright: © 2023 Termedia Sp. z o. o.)
- Published
- 2023
- Full Text
- View/download PDF
43. Does the induction immunotherapy (basiliximab) influence the early acute cellular rejection index after orthotopic heart transplantation?- Preliminary assessment report.
- Author
-
Kuczaj A, Warwas S, Zakliczyński M, Pawlak S, Przybyłowski P, Śliwka J, and Hrapkowicz T
- Subjects
- Male, Adult, Humans, Middle Aged, Female, Basiliximab therapeutic use, Tacrolimus, Everolimus, Graft Rejection, Immunosuppressive Agents therapeutic use, Immunotherapy, Recombinant Fusion Proteins therapeutic use, Heart Transplantation, Renal Insufficiency
- Abstract
The study aimed to determine the influence of induction therapy on the acute cellular rejection (ACR) index in adult heart transplant recipients during the one-year observation. The study population consisted of 256 consecutive adult patients (pts), aged 51.5 (±11.9) years, 199 (77%) men treated with orthotopic heart transplantation (OHT) in the period between 2015 and 2020 in a single high-volume heart transplant center. The endomyocardial biopsies (EMBs) were performed according to the protocol consisting of 7 protocolary EMBs for up to 3 months and 10 EMBs for up to one year after OHT. The rejection index (ACRI) was calculated as the number of scheduled EMBs with the ACR ≥ 2 divided by the total number of protocolary EMBs. The study population was divided into two groups according to the application of basiliximab. The total number of pts. who received basiliximab was 10 (3.9%). The main indications for the usage of the induction therapy were heart retransplantation, mechanical circulatory support (MCS), severe renal insufficiency (eGFR <30 mL/min/1.73 m2), and a panel of reactive antibody (PRA) > 10%. In the group with induction, the mean age was 49 (±14) years; 3 (30%) patients had the MCS prior to OHT, and 3 (30%) patients had heart retransplantation. Four (40%) patients had diabetes mellitus, and 4 (40%) patients had severe renal insufficiency. As maintenance therapy during the observation period, tacrolimus was given to 10 (100%) patients, everolimus to 2 (20%) patients, and MPA to 9 (90%) patients. In the group with no induction, the mean age was 51.8 (±12) years, MCS was used in 56 (23%) patients, 2 (0.8%) patients were retransplanted; 10 (4%) patients had eGFR <30 mL/min/1.73 m2 and 58 (24%) patients had diabetes. Tacrolimus was administered to 243 (99%) patients, cyclosporine to 3 (1%), everolimus to 40 (16%), and mycophenolate to 245 (99.6%) heart recipients. The median one-year ACRI was 0.0, IQR:0.0-0.08 in the group with induction vs. 0.077, IQR: 0.0-0.154 with no induction; p = 0.11. ACRI up to three months was significantly higher in the entire cohort in comparison to up to one year (P < 0.01). The multivariate analysis showed that only everolimus implementation and younger age at the time of transplant influenced patients' mortality rate (P < 0.01). Significant graft rejections (≥ 2R ISHLT) are most common in the first three months after OHT. Patients who are initially at high risk of significant cellular rejection may benefit from induction therapy., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
44. Gut Microbiome in Patients after Heart Transplantation-Current State of Knowledge.
- Author
-
Olek K, Kuczaj AA, Warwas S, Hrapkowicz T, Przybyłowski P, and Tanasiewicz M
- Abstract
The human gut microbiota include over 10 trillion microorganisms, such as bacteria, fungi, viruses, archaea, and protozoa. Many reports indicate the strong correlation between dysbiosis and the severity of cardiovascular diseases. Microbiota seem to interact with the host's alloimmunity and may have an immunomodulatory role in graft rejection processes. In our study, we present the current state of the knowledge of microbiota in heart transplant recipients. We present up-to-date microbiota diagnostic methods, interactions between microbiota and immunosuppressive drugs, the immunomodulatory effects of dysbiosis, and the available strategies (experimental and clinical strategies) to modulate host microbiota.
- Published
- 2023
- Full Text
- View/download PDF
45. Novel Hybrid Treatment for Pulmonary Arterial Hypertension with or without Eisenmenger Syndrome: Double Lung Transplantation with Simultaneous Endovascular or Classic Surgical Closure of the Patent Ductus Arteriosus (PDA).
- Author
-
Stącel T, Sybila P, Mędrala A, Ochman M, Latos M, Zawadzki F, Pióro A, Pasek P, Przybyłowski P, Hrapkowicz T, Mroczek E, Kuczaj A, Kopeć G, Fiszer R, Pawlak S, Stanjek-Cichoracka A, and Urlik M
- Abstract
Patients with pulmonary arterial hypertension (PAH) become candidates for lung or lung and heart transplantation when the maximum specific therapy is no longer effective. The most difficult challenge is choosing one of the above options in the event of symptoms of right ventricular failure. Here, we present two female patients with PAH: (1) a 21-year-old patient with Eisenmenger syndrome, caused by a congenital defect-patent ductus arteriosus (PDA); and (2) a 39-year-old patient with idiopathic PAH and coexistent PDA. Their common denominator is PDA and the hybrid surgery performed: double lung transplantation with simultaneous PDA closure. The operation was performed after pharmacological bridging (conditioning) to transplantation that lasted for 33 and 70 days, respectively. In both cases, PDA closure effectiveness was 100%. Both patients survived the operation (100%); however, patient no. 1 died on the 2nd postoperative day due to multi-organ failure; while patient no. 2 was discharged home in full health. The authors did not find a similar description of the operation in the available literature and PubMed database. Hence, we propose this new treatment method for its effectiveness and applicability proven in our practice.
- Published
- 2022
- Full Text
- View/download PDF
46. Assessment of Anti-Human Leukocyte Antigen (HLA)-Antibody-Dependent Humoral Response in Patients before and after Lung Transplantation.
- Author
-
Stanjek-Cichoracka A, Ochman M, Chełmecka E, and Hrapkowicz T
- Subjects
- Humans, HLA Antigens, Immunoglobulin G, Graft Rejection prevention & control, Lung Transplantation, Kidney Transplantation
- Abstract
Background and Objectives : Testing for anti-human leukocyte antigen (HLA) antibodies both before and after transplantation is of fundamental significance for the success of lung transplantation. The aim of this study was the evaluation of anti-HLA immunization of patients before and after lung transplant who were subjected to qualification and transplantation. Materials and Methods : Prior to the transplantation, patients were examined for the presence of IgG class anti-HLA antibodies (anti-human leukocyte antigen), the so-called panel-reactive antibodies (PRA), using the flow cytometry method. After the transplantation, the class and specificity of anti-HLA antibodies (also IgG) were determined using Luminex. Results : In the group examined, the PRA results ranged from 0.1% to 66.4%. Low (30%) and average (30-80%) immunization was found in only 9.7% of the group examined. Presence of class I anti-HLA antibodies with MFI (mean fluorescence intensity) greater than 1000 was found in 42.7% of the patients examined, while class II anti-HLA antibodies were found in 38.4%. Immunization levels before and after the transplantation were compared. In 10.87% of patients, DSA antibodies (donor-specific antibodies) with MFI of over 1000 were found. Conclusions : It seems that it is possible to confirm the correlation between pre- and post-transplantation immunization with the use of the two presented methods of determining IgG class anti-HLA antibodies by increasing the size of the group studied and conducting a long-term observation thereof.
- Published
- 2022
- Full Text
- View/download PDF
47. Clinical insights into the role of immunosuppression in solid organ transplant recipients with COVID-19.
- Author
-
Kolonko A, Kuczaj AA, Musialik J, Słabiak-Błaż N, Hrapkowicz T, Przybyłowski P, and Więcek A
- Subjects
- Humans, Immunosuppression Therapy adverse effects, Immunosuppressive Agents adverse effects, Pandemics, SARS-CoV-2, Transplant Recipients, COVID-19, Organ Transplantation adverse effects
- Abstract
Introduction: The COVID-19 pandemic has disproportionately affected patients who have undergone solid organ transplantation (SOT)., Objectives: We aimed to assess a cohort of transplant recipients who developed COVID‑19, with a focus on immunosuppressive regimen, blood tacrolimus levels, clinical course, and patient and graft outcomes., Patients and Methods: During the first 12 months of the pandemic, we identified ambulatory SOT recipients, including kidney, liver, and heart transplant recipients, diagnosed with SARS‑CoV‑2 infection. Baseline and follow‑up data on graft function, immunosuppression, and patient and graft outcomes were assessed., Results: Of the 2091 ambulatory patients, we identified 201 transplant recipients (9.6%) with SARS‑CoV‑2 infection (kidney transplant, n = 112; heart transplant, n = 56; liver transplant, n = 33). Patients after recent kidney (during 2015-2020) or heart (during 2020) transplant were significantly more often diagnosed with COVID ‑19 than patients with a longer time since transplant. Additionally, blood trough tacrolimus levels measured during or shortly after COVID‑19 in 23 kidney graft recipients were significantly increased by a median of 76.1% (interquartile range, 47.4%-109.4%) relative to predose trough levels. However, liver function parameters were not elevated, necessitating a tacrolimus dose reduction in 73.9% of the patients., Conclusions: In our study, kidney transplant recipients showed significant disturbances of tacrolimus metabolism, which may account for kidney function worsening during COVID‑19. Moreover, infection was more common in patients with recent kidney or heart transplant, which suggests that the level of immunosuppression may affect morbidity related to SARS‑CoV‑2 infection.
- Published
- 2022
- Full Text
- View/download PDF
48. Factors associated with cardiac allograft vasculopathy after heart transplantation.
- Author
-
Szczurek-Wasilewicz W, Hawranek M, Skrzypek M, Hrapkowicz T, Gąsior M, Warmusz O, and Szyguła-Jurkiewicz B
- Abstract
Introduction: Cardiac allograft vasculopathy (CAV) is a major threat to long-term survival after heart transplantation (HT)., Aim: To determine factors associated with CAV detection in patients after HT., Material and Methods: We analyzed 299 consecutive patients after HT who underwent routine visits at our institution between 2016 and 2018. Human interleukin 33 (IL-33) and suppression of tumorigenicity 2 (ST2) were measured by sandwich enzyme-linked immunosorbent assay with a commercially available kit (Human ST-2 and IL-33 ELISA, SunRedBio Technology Co, Ltd, Shanghai, China)., Results: The patients' median age was 59.00 years, and 74.2% were men. The frequency of CAV was 47.5%. Multivariable logistic regression analysis showed that IL-33 (odds ratio (OR) = 1.044 (1.029-1.059), p < 0.001) and ST2 (OR = 1.061 (1.040-1.083), p < 0.001) serum concentrations, donor age (OR = 1.046 (1.009-1.085), p = 0.015), left ventricular diastolic dimension (LVDD) (OR = 1.081 (1.016-1.149), p = 0.013), and time from HT to blood collection (OR = 1.256 (1.151-1.371), p < 0.001) were independent risk factors for CAV. The area under the receiver operating characteristics curve (AUC) indicated good prognostic power of IL-33 and ST2 concentrations (AUC = 0.779 and AUC = 0.784, respectively) and excellent prognostic power of the IL-33/ST2 score (AUC = 0.863)., Conclusions: Lower IL-33 and higher ST2 serum concentrations, as well as older donor age, larger LVDD and longer time from HT to blood collection, are independently associated with CAV. IL-33 and ST2 have good discriminatory power and the IL-33/ST2 score has excellent strength for detecting CAV., Competing Interests: The authors declare no conflict of interest., (Copyright: © 2022 Termedia Sp. z o. o.)
- Published
- 2022
- Full Text
- View/download PDF
49. Ministernotomy for aortic valve replacement improves early recovery and facilitates proper wound healing - forced propensity score matching design with reference full sternotomy.
- Author
-
Kaczmarczyk M, Pacholewicz J, Kaczmarczyk A, Filipiak K, Hrapkowicz T, and Zembala M
- Abstract
Introduction: With the development of less invasive techniques ministernotomy has become an increasingly popular choice for minimally invasive aortic valve replacement (MIAVR). However, a large discrepancy in the published results, often derived from the center's own experience, intensifies the need for further re-evaluation in order to better define the real impact of the ministernotomy approach on postoperative clinical condition in short- and long-term observation., Aim: To assess the safety and efficacy of MIAVR in comparison to a reference full sternotomy AVR (FSAVR)., Material and Methods: Between January 2004 and January 2018, 2386 patients underwent isolated surgical aortic valve replacement (AVR) at our institution. 620 patients were treated minimally invasively (MIAVR) and 1766 patients received FSAVR. Forced propensity score 1 : 1 matching and conditional regressive methods were introduced, ensuring valid comparison and correct estimation. Ultimately, 557 well allocated pairs of treated and control patients were included., Results: In-hospital mortality was low and comparable (1.26% for MIAVR, 1.62% for FSAVR). No significant differences in terms of serious adverse events were found, although in patients undergoing MIAVR there tended to be lower incidence of neurological complications (OR = 0.72; p = 0.09) and low output syndrome (OR = 0.66; p = 0.13). In addition to a much faster extubation and discharge from the ICU as well as improved blood management, MIAVR significantly reduced the risk of wound complications (OR = 0.31; p < 0.0010)., Conclusions: MIAVR is a safe, effective and reproducible procedure providing at least as good results as FSAVR. Nevertheless, it should be especially recommended to obese, diabetic patients with pulmonary and mobility disorders in order to improve their early recovery., Competing Interests: The authors report no conflict of interest., (Copyright: © 2022 Polish Society of Cardiothoracic Surgeons (Polskie Towarzystwo KardioTorakochirurgów) and the editors of the Polish Journal of Cardio-Thoracic Surgery (Kardiochirurgia i Torakochirurgia Polska).)
- Published
- 2022
- Full Text
- View/download PDF
50. Patient-Related Preoperative Clinical Factors Influencing 1-Year Survival After Orthotopic Heart Transplantation - A Single Center Polish Experience.
- Author
-
Kuczaj A, Pawlak S, Przybyłowski P, Warwas S, Śliwka JE, Zakliczyński M, and Hrapkowicz T
- Subjects
- Female, Humans, Poland, Retrospective Studies, Risk Factors, Treatment Outcome, Heart Failure etiology, Heart Failure surgery, Heart Transplantation adverse effects, Heart-Assist Devices
- Abstract
BACKGROUND End-stage heart failure is a growing problem in Poland. Orthotopic heart transplantation remains the best treatment option. Although increasing, the number of heart transplants is disproportionately low compared with patient need. Therefore, it is crucial to identify factors contributing to improvement of heart transplantation outcomes. To find factors providing best survival and optimal recipient selection, we analyzed pretransplant patient-related clinical factors. MATERIAL AND METHODS Between May 2015 and May 2020, we performed 258 cardiac transplants at our institution. We reviewed possible patient-related clinical factors affecting the 1-year survival of our patients and analyzed factors related to survival. Mean age at transplant was 53.5 (±11.8) years; 22.9% of patients were women. Preoperative factors were analyzed using univariable and multivariable analyses. RESULTS In this cohort, 31.8% were diabetic, 43% had ischemic etiology of heart failure, and 15.3% had reversible pulmonary hypertension. Mechanical circulatory support was used in 22%. During 1-year observation, 64 (24.8%) patients died. Univariable analysis showed ischemic etiology (hazard ratio [HR]=2.05, CI=1.227-3.429; P=0.01) and left ventricular assist device were associated with 1-year risk of death (HR=1.953, CI=1.090-3.499; P=0.02). Urgent listing trended toward worsened prognosis (HR=1.509, CI=0.95-2.397; P=0.08). Multivariable analysis showed ischemic etiology (HR=1.81, CI=1.075-3.059; P=0.03), total mechanical circulatory support (HR=1.93, CI=1.080-3.437; P=0.03), decreased eGFR (HR=0.987, CI=0.975-0.998; P=0.03), and protein level (HR=0.97, CI=0.951-0.998; P=0.04) were independently associated with worse 1-year survival after transplantation. CONCLUSIONS Ischemic etiology and mechanical circulatory support were the most important preoperative factors. Malnutrition and renal failure were additional risk factors. Age alone did not influence 1-year survival.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.